FOLH1 and prostate cancer: We, our collaborators from Radboud University Medical Center/the University of Nijmegen, and others have reported that PET/CT at ≥ 24 h post-injection with [89Zr]Zr-PSMA-617 or other 89Zr-labeled tracers frequently detects lesions suspicious for prostate cancer that were not apparent on conventionally-acquired PET/CT images [11–16].